Sera Prognostics Stock Return On Equity
| SERA Stock | USD 2.91 0.02 0.68% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Sera Prognostics' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Sera Prognostics Company Return On Equity Analysis
Sera Prognostics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sera Prognostics Return On Equity | -0.56 |
Most of Sera Prognostics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sera Prognostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sera Prognostics has a Return On Equity of -0.5578. This is 97.67% lower than that of the Biotechnology sector and 91.65% lower than that of the Health Care industry. The return on equity for all United States stocks is 79.94% higher than that of the company.
Sera Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sera Prognostics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sera Prognostics could also be used in its relative valuation, which is a method of valuing Sera Prognostics by comparing valuation metrics of similar companies.Sera Prognostics is currently under evaluation in return on equity category among its peers.
Sera Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (392.62) % | ||||
| Current Valuation | 64.22 M | ||||
| Shares Outstanding | 36.7 M | ||||
| Shares Owned By Insiders | 12.90 % | ||||
| Shares Owned By Institutions | 64.23 % | ||||
| Number Of Shares Shorted | 785.95 K | ||||
| Price To Book | 2.31 X | ||||
| Price To Sales | 1,424 X | ||||
| Revenue | 77 K | ||||
| Gross Profit | (5 K) | ||||
| EBITDA | (32.04 M) | ||||
| Net Income | (32.9 M) | ||||
| Cash And Equivalents | 106.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 840 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.80 X | ||||
| Book Value Per Share | 1.40 X | ||||
| Cash Flow From Operations | (14.19 M) | ||||
| Short Ratio | 7.78 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Target Price | 2.75 | ||||
| Number Of Employees | 63 | ||||
| Beta | 0.97 | ||||
| Market Capitalization | 109.62 M | ||||
| Total Asset | 72.58 M | ||||
| Retained Earnings | (279.79 M) | ||||
| Working Capital | 22.83 M | ||||
| Net Asset | 72.58 M |
About Sera Prognostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sera Prognostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sera Prognostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sera Prognostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sera Prognostics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sera Prognostics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sera Prognostics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sera Prognostics Stock:Check out Sera Prognostics Piotroski F Score and Sera Prognostics Altman Z Score analysis. For information on how to trade Sera Stock refer to our How to Trade Sera Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Healthcare space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sera Prognostics. If investors know Sera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sera Prognostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sera Prognostics is measured differently than its book value, which is the value of Sera that is recorded on the company's balance sheet. Investors also form their own opinion of Sera Prognostics' value that differs from its market value or its book value, called intrinsic value, which is Sera Prognostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sera Prognostics' market value can be influenced by many factors that don't directly affect Sera Prognostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sera Prognostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sera Prognostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sera Prognostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.